Abstract
The release of the new ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing has led to clearer descriptive definitions for immunohistochemistry categories. As soon as we started to use them we realized that an increase in the number of ISH test was occurring. Herein we report our lab data obtained by comparing the semester after the release of the new guidelines with the same semester of the previous year. The impact on routine work practice is highlighted.
| Original language | English |
|---|---|
| Pages (from-to) | 285-286 |
| Number of pages | 2 |
| Journal | THE BREAST |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Surgery
Keywords
- ASCO/CAP
- Breast Neoplasms
- Early Detection of Cancer
- ErbB-2
- Female
- Guidelines
- HER2
- Humans
- Neoplasm Proteins
- Physicians'
- Practice Guidelines as Topic
- Practice Patterns
- Receptor
Fingerprint
Dive into the research topics of '2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver